JP Morgan upgrades two biotech companies amid 'optimistic' outlook

J.P. Morgan alerted clients to two biotech companies that it believes could outperform peers in the next year.

“Overall, we remain optimistic about the outlook for biotech in 2018, despite recent volatility giving back some early outperformance to start the year,” wrote analyst Cory Kasimov on Wednesday. “Indeed, the combination of continued innovation, a constructive FDA, and ready access to capital markets, all under the auspices of an omnipresent M&A backdrop, presents a compelling setup.”

Here are the two stocks J.P. Morgan upgraded to overweight during the firm’s ongoing rating rebalancing.

Let’s block ads! (Why?)

Health Care

Related posts:

%d bloggers like this: